We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Testing Method Clinically Ascertains Genetic Basis for Hypercholesterolemia

By LabMedica International staff writers
Posted on 03 Nov 2016
Print article
Next-generation sequencing technology is transforming our understanding of heterozygous familial hypercholesterolemia, including revision of prevalence estimates and attribution of polygenic effects.

The use of next-generation sequencing (NGS) technology has pinpointed specific areas of a person's DNA to more effectively diagnose genetic forms of high-cholesterol, which markedly increase risk for heart attack and stroke.

Scientists at University of Western Ontario (London, ON, Canada) and their colleagues examined the contributions of monogenic and polygenic causes in patients with severe hypercholesterolemia referred to a specialty clinic. They applied targeted next-generation sequencing with custom annotation, coupled with evaluation of large-scale copy number variation and polygenic scores for raised low-density lipoprotein cholesterol in a cohort of 313 individuals with severe hypercholesterolemia, defined as low-density lipoprotein cholesterol greater than 5.0 mmol/L (>194 mg/dL).

DNA samples were assessed by visualization on a 1% agarose gel and using a NanoDrop 1000 spectrophotometer, and the DNA was then and measured using a Qubit 2.0 fluorometer. The new genetic testing method called LipidSeq was able to identify a genetic mutation in 67% of the patients. They found that 54% were single gene mutations, and the other 13% were polygenic DNA variants, meaning they were a combination of multiple bad genes inherited together. The study also showed that the percentage of individuals with an identified genetic component increased as cholesterol levels in the patient increased. The percentage of individuals with an identified genetic component increased from 57.0% to 92.0% as low-density lipoprotein cholesterol level increased from 5.0 to >8.0 mmol/L (194 to >310 mg/dL).

Robert A. Hegele, MD, FRCPC, a professor of Endocrinology and the senior author of the study, said, “This new method provides a more cost-effective way to find these genetic links rather than sequencing the entire genome. By pre-identifying patients who have a personal and familial history of high-cholesterol, LipidSeq was able to find a genetic mutation in 67 % of those tested. This new method shows there is a benefit, especially when you can add the extra step of medically selecting those with a familial history of the disease.” LipidSeq has already been licensed for use in the USA to help clinicians identify patients with genetically-based high-cholesterol in order to guide drug prescriptions. The study was published on October 20, 2016, in the journal Arteriosclerosis, Thrombosis, and Vascular Biology.

Related Links:
University of Western Ontario


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.